Advancing CAR T-Cell Therapy
JAMA · 06.01.2026 · 335 (1) · 21
DOI: 10.1001/jama.2025.21721 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 06.01.2026. Verfasst von Upendra Mahat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Evaluation Hematology, Office of Clinical Evaluation, Center for Biologic Evaluation and Research, Food and Drug Administration,…. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the recent decision by the US Food and Drug Administration to eliminate Risk Evaluation and Mitigation Strategies requirements for chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer.
Autor:innen und Institutionen
- Division of Clinical Evaluation Hematology, Office of Clinical Evaluation, Center for Biologic Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
- Office of Clinical Evaluation, Center for Biologic Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
- Office of Therapeutic Products, Center for Biologic Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
- Center for Biologic Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland.
Zitieren
APA
Mahat, U., Das, A., Kumar, V., & Prasad, V. (2026). Advancing CAR T-Cell Therapy. JAMA, 335(1), 21. https://doi.org/10.1001/jama.2025.21721
Vancouver
Mahat U, Das A, Kumar V, Prasad V. Advancing CAR T-Cell Therapy. JAMA. 2026;335(1):21. doi:10.1001/jama.2025.21721
BibTeX
@article{Mahat2026,
author = {Mahat, Upendra and Das, Asha and Kumar, Vijay and Prasad, Vinay},
title = {Advancing CAR T-Cell Therapy},
journal = {JAMA},
year = {2026},
volume = {335},
number = {1},
pages = {21},
doi = {10.1001/jama.2025.21721}
}
EUVIMED